Derfor kan interaktion med peroralt administrerede lægemidler til kemoterapibehandling, som primært eller delvist metaboliseres ved hjælp af CYP3A4 (fx etoposid, vinorelbin), ikke udelukkes.
Because the effect of aprepitant on the pharmacokinetics of orally administered CYP3A4 substrates is greater than the effect of aprepitant on the pharmacokinetics of intravenously administered CYP3A4 substrates, an interaction with orally administered chemotherapeutic agents metabolised primarily or in part by CYP3A4 (e. g., etoposide, vinorelbine) cannot be excluded.